Breaking News

MilliporeSigma Launches Mobius ADC Reactor

Addresses the unique challenges associated with ADC manufacturing, providing biopharmaceutical companies with a more efficient and safer solution.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has launched its Mobius ADC Reactor, a single-use reactor specifically designed for the production of antibody drug conjugates (ADCs). ADCs, a rapidly growing class of therapeutic agents, offer targeted and selective killing of tumor cells while minimizing harm to healthy tissues.
 
The Mobius ADC Reactor addresses the unique challenges associated with ADC manufacturing, providing biopharmaceutical companies with a more efficient and safer solution. By eliminating the need for labor-intensive cleaning procedures required by traditional stainless steel or glass reactors, the single-use technology offers faster turnaround times and reduced risk of cross-contamination.
 
“We have been providing single-use solutions for flexible biopharmaceutical manufacturing for more than 15 years. Drawing on this extensive experience, we are now ready to accelerate the production of antibody-drug conjugates,” said Sebastian Arana, Head of Process Solutions, Life Science business of Merck KGaA, Darmstadt, Germany. “The launch of the Mobius ADC Reactor will support our customers to bring much-needed therapies to a global population.”
 
The new reactor features innovative design elements, including the use of Ultimus Film technology for enhanced bag strength and durability. This technology, combined with optimized chemical compatibility and quality standards, ensures high product quality while minimizing waste.
 
Merck KGaA’s comprehensive offering for ADC manufacturing includes a range of single-use systems, consumables, and services. The Mobius single-use systems for chromatography and tangential flow filtration (TFF) are particularly suited for closed-mode operations, while the Pellicon capsule provides essential consumables. Additionally, the company offers contract development and manufacturing organization (CDMO) services, as well as testing services for ADCs and high-potent active pharmaceutical ingredients (HPAPIs).

More MilliporeSigma News

MilliporeSigma recently signed a definitive agreement to acquire Mirus Bio for $600 million.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters